Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor
About this episode
Thijs Spoor discusses the resurgence of radiopharmaceuticals and the importance of biodistribution in therapeutic production.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Thijs Spoor, CEO at Perspective Therapeutics, a company developing Pb 212 (lead)-based therapeutics, talks about why radiopharmaceuticals are surging again and why biodistribution is the make-or-break variable when your payload is a radioactive isotope. Thijs discusses the reasons behind Perspective's investment in a proprietary generator for therapeutic production, manufacturing a...
More episodes of Business Of Biotech
- Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary
- The Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw
- Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.
- Investing In Early-Stage Oncology With Yosemite's Dan McHugh
- Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash
- Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.
Explore listener stats, chart rankings, contacts and more on the Business Of Biotech podcast page.